Please ensure Javascript is enabled for purposes of website accessibility

Merck (Finally) Starts a Clinical Trial of its Coronavirus Vaccine

By Brian Orelli, PhD – Sep 13, 2020 at 10:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Better late than never.

Multiple drugmakers are in phase 3 clinical trials for their coronavirus vaccines -- the last stage before potential approval. Meanwhile, Merck (MRK 0.55%) is just now starting the first human study of its coronavirus vaccine, V591.

Being so far behind, the company didn't even bother announcing the start of the phase 1/2 clinical trial. The Wall Street Journal noticed the new clinical trial in the U.S. government's database, which was updated on Sept. 9.

While speed is important in a pandemic, Merck deserves get a bit of a break for its relatively slow start. The company only got its hands on the vaccine technology after acquiring a privately held Austrian company called Themis Bioscience in May.

Themis' technology, which was licensed from the French research nonprofit Institut Pasteur, uses a modified measles virus to deliver antigens to the immune system. In the case of V591, the antigen would help the patient develop antibodies against the novel coronavirus that causes COVID-19.

Nurse showing a syringe to a child

Image source: Getty Images.

Merck's clinical trial, which is being run in Belgium, will enroll up to 260 participants who will be treated with different dosing regimens, which could include a single shot as well as two-dose regimens with booster shots on day 57 or day 169.

The booster regimen of V591 is substantially prolonged compared to Pfizer (PFE 0.52%) and BioNTech's (BNTX -0.92%) 21-day booster and Moderna's (MRNA 0.98%) 28-day booster.

The extended time to a booster will delay clinical trial results but could also be a benefit Merck if the patient is fully protected in the time between the first dose and the booster. Better yet, there's the possibility that a single dose will be enough to fully protect patients from COVID-19.

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.